Articles tagged with Parkinsons Disease
Michel Goedert's research focuses on protein aggregates in Alzheimer's and Parkinson's, providing deep insights into disease development. His work is essential for finding new treatments, as evidenced by his discovery of gene mutations leading to dementia.
A study published in Aging-US reveals that protein processing impairment in Parkinson's disease is mediated by chromogranin/secretogranin, leading to decreased candidate proteins and peptides. This finding suggests a potential therapeutic target for the treatment of PD.
A recent study suggests that targeting alpha-synuclein protein in Parkinson's disease may not be sufficient to cure most patients. Instead, resolving brain inflammation caused by dysfunctional interferon-beta receptor signaling may hold the key to developing more effective treatments.
Researchers at Carnegie Mellon University have found a way to make deep brain stimulation (DBS) more precise, resulting in therapeutic effects that outlast what is currently available. The new protocol uses short bursts of electrical stimulation to target specific neuronal subpopulations, providing longer-lasting benefits.
Scientists have developed an improved technique to trace brain connections between neurons in zebrafish using vesicular stomatitis virus (VSV), enabling the visualization of connected neurons up to five days after infection. This breakthrough could provide insights into brain network connectivity repair after injury or disease.
A new study found that toxic fatty acids produced by astrocytes can trigger cell death in damaged neurons, which may contribute to neurodegenerative diseases such as glaucoma and Alzheimer's. Blocking the production of these fatty acids in mice preserved 75% of neurons, suggesting a promising target for treatment.
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
The Michael J. Fox Foundation has defined four major areas of action to reduce health disparities and advance treatments for everyone with PD. The foundation is launching a new funding opportunity to study incidence, etiology, and pathology in underrepresented populations.
Researchers highlight current strategies to restore lost function and replace what is lost in the PD brain, including cell and gene therapy approaches. Pioneering trials face regulatory and ethical challenges that require incremental development and step-wise optimization of products.
Researchers at The Graduate Center, CUNY, found that increased signaling of the sonic hedgehog protein can inhibit LID in animal models of Parkinson's disease. This could lead to a potential therapeutic solution for most Parkinson's patients.
Researchers have identified a molecule that slows cells' production of alpha-synuclein, a protein forming toxic aggregates in Parkinson's brains. The compound, A-443654, also reduces cell stress and may help degrade existing alpha-synuclein aggregates.
Researchers at Rush University Medical Center have developed potential new treatments for Parkinson’s disease that showed success in slowing its progression in mice. The lab-developed peptides helped slow the spread of alpha-synuclein, a protein that occurs in abnormal deposits in the brain.
The USC Institute is launching a $3 million global consortium study to analyze brain imaging, genetics, and clinical data from 20 countries. The study aims to understand how Parkinson's disease progresses in the brain and explore genetic factors contributing to risk.
Researchers at the University of Helsinki have identified two distinct patterns of alpha-synuclein accumulations in the olfactory bulb, associated with differing disease types of dementia with Lewy bodies. These findings support the classification of the disease into two distinct forms, one progressing to the amygdala and another to th...
Researchers surveyed 4,324 people with Parkinson's and found that many are unaware of all seven compensation strategies, but most who tried them reported positive effects. The study suggests a 'one-size-fits-all' approach doesn't work, emphasizing the need for personalized education on available strategies.
Researchers created tiny human midbrain-like organoids that mimic the major pathological features of Parkinson's disease. These organoids enable scientists to study how the human brain develops and communicates, providing insights into the progression of the disease and potential new treatments.
Researchers developed a new AI algorithm called 'basis profile curve identification' to simplify comparisons between effects of electrical stimulation on the brain. The algorithm may help understand which brain regions interact with each other, guiding placement of electrodes for treating network brain diseases.
A new unsupervised machine learning algorithm, B-SOiD, developed by Carnegie Mellon University researchers makes studying animal behavior more accurate and efficient. The algorithm identifies patterns in an animal's body position to discover behaviors, removing human error and bias.
A new European survey sheds light on the lives of people with Parkinson's disease and their carers, revealing a wide range of non-motor symptoms affecting quality of life. The study highlights the importance of individualized management and improved clinical practice in addressing the unique challenges faced by patients and caregivers.
A new study found that patients with advanced Parkinson's disease are at higher risk of contracting and suffering from respiratory illnesses like influenza and pneumonia. Neurologists are advised to actively encourage vaccinations for these patients, particularly in the light of COVID-19.
Researchers discovered that a brain area traditionally thought to specialize in old habits also plays a role in learning new actions. The study found that the dorsolateral striatum is involved in consolidating action learning immediately after the new action has been learned.
Researchers identified physical binding sites for cholesterol in GIRK channels, which play a role in neurodegenerative diseases. The study provides structural insights into how cholesterol alters channel function, paving the way for drug development.
A study found that transcranial stimulation can increase the benefits of aerobic exercise and improve gait in Parkinson's patients. The treatment uses a weak current delivered by electrodes placed over specific brain regions, activating the pre-frontal cortex.
A new UBCO study determines that wearable technology and telehealth can tailor treatment plans for Parkinson's disease by identifying peak times of symptoms. The research found positive experiences and health outcomes for patients using wearable devices in combination with telehealth appointments.
Impaired information flow through the basal ganglia is responsible for Parkinson's disease symptoms. The 'direct pathway' plays a crucial role in initiating voluntary movements, and its disturbance leads to motor symptoms like trembling hands and muscle stiffness.
Researchers at Niigata University have identified a key pathway involving the protein optineurin that may contribute to the development of amyotrophic lateral sclerosis (ALS) disease. The study found that optineurin inhibits the formation of stress-induced TDP-43 protein aggregates in motor neurons, which are a hallmark of ALS.
Researchers at Oregon Health & Science University have successfully used a synthetic compound to regulate the TREM2 gene, implicated in neurodegenerative diseases. The findings raise hope for developing new treatments for Alzheimer’s and Parkinson’s.
Scientists discovered a new mitochondrial recycling pathway that may help prevent Parkinson's disease. The study, published in Science Advances, reveals that genes associated with Parkinson's disease play key roles in this process and that disruptions can contribute to neurodegeneration.
A study in mice shows that an experimental small molecule helped restore the removal of damaged mitochondria from dopamine-producing brain cells, which may help explain what goes wrong in people with mutations that cause Parkinson's disease. The findings highlight the potential benefit of LRRK2 inhibitors as treatments for the disease.
Researchers found that farnesol prevents loss of dopamine neurons and reverses behavioral deficits in mice, indicating its potential as a drug treatment for Parkinson's disease. The compound blocks the PARIS protein, which is involved in the progression of the disease.
Researchers have discovered distinct populations of neurons in the mesencephalic locomotor region that control different body movements. These findings could improve therapies for Parkinson's disease by targeting specific neuronal populations involved in postural changes and body extension.
A study published in Annals of Neurology found the SNCA gene has genome-wide significance in Latino PD patients, while a novel gene NRROS is identified as a potential risk factor. The research also shows a substantial overlap of PD genetic architecture between Europeans and Latinos.
A gene therapy trial has shown significant improvements in children with primary AADC deficiency, a devastating genetic disorder characterized by severe motor disability and developmental delay. The treatment targets neurons that produce dopamine, resulting in improved motor function, better mood, and longer sleep.
A non-toxic derivative of tetanus neurotoxin improves depression symptoms in rat models, lasting two weeks. Hc-TeTx inhibits serotonin transport by binding to neurotrophin receptors, suggesting potential for treating neurodegenerative diseases.
Researchers from UCPH discovered that a blockage in the pathway regulating nerve cell powerhouses, mitochondria, is the major cause of sporadic Parkinson's Disease. This dysregulation leads to accumulation of damaged mitochondria and neuronal death, resulting in dementia.
A new study shows participating in weekly dance training with music can improve daily living and motor function for those with mild-to-moderate Parkinson's disease. The research found significant improvements in experiences of daily living, including cognitive impairment, hallucinations, depression, and anxious mood.
A human endogenous peptide called LL-37 has been identified as a powerful blocker of toxic α-synuclein oligomers, which are responsible for neurodegeneration in Parkinson's disease. The discovery suggests that this naturally occurring molecule could be a safe and effective therapy to slow down the progression of the disease.
Researchers found no protection against Parkinson's and Lewy body dementias when reducing tau protein in brain neurons. Instead, the study highlights distinct roles of tau in these diseases compared to Alzheimer's, where reducing endogenous tau levels is protective.
Researchers discover that cytosolic dsDNA from mitochondria can cause cell death and neurodegeneration in PD patients. A new approach using DNAse II may help counteract this effect, potentially leading to a breakthrough in treating Parkinson's Disease.
A retrospective study of 33,360 patients found a 41% increased risk of Parkinson's disease in those with osteoarthritis. Patients with knee or hip osteoarthritis had a higher risk compared to others.
A study by Van Andel Institute and Roche suggests that chronic gut inflammation may propel processes in the body leading to Parkinson's disease. The researchers found that gut inflammation triggers protein clumping in the colon and brain, which can clog molecular machinery and lead to Parkinson's symptoms.
Researchers developed an AI system that analyzes 3D brain images to diagnose Parkinson's disease stages, providing a more precise diagnosis. The tool combines AI and 3D imaging to estimate severity based on neuronal damage.
Researchers found significant improvement in motor symptoms and reduction in medications 15 years after deep brain stimulation for Parkinson's disease patients. The study also showed a reduction in dyskinesia and 'off state' episodes, improving quality of life.
Scientists create synthetic melanin-like nanoparticles to overcome limitations of current dopamine delivery methods, achieving efficient and controlled release in the brain. The proposed method demonstrates promising results in reversing Parkinson's symptoms with high biocompatibility and non-toxicity.
University of Guelph researchers have discovered how entangled proteins in brain cells enable Parkinson's disease to spread. Misfolded alpha-synuclein aggregates spread to other parts of the brain, impairing areas responsible for motor function and cognition.
A research team identified the structure of hetero-oligomers causing Alzheimer's and Parkinson's diseases to overlap. The study reveals that these aggregates have more degrees of freedom, allowing peptides to be loosely packed on their surface.
A rare mutation causes Parkinson's disease-like symptoms by disrupting dopamine transport, suggesting treatments targeting the transporters could alleviate symptoms. A malaria drug helps alleviate movement problems in genetically modified fruit flies with the mutation.
Patients with REM sleep behavior disorder show signs of low blood flow and cognitive decline, suggesting a link between disrupted sleep and Parkinson's symptoms. The study aims to investigate the relationship between reduced blood flow and Parkinson's disease progression.
Researchers at the University of York developed a gel that adheres to nasal tissue, delivering levodopa directly to the brain. This innovation improves drug effectiveness and reduces dosage needs, potentially benefiting patients with Parkinson's disease.
Understanding how tau protein is regulated in brain cells could lead to better treatments for Parkinson's and other neurological conditions. Researchers discovered that similar lncRNAs control the production of tau and other key proteins involved in brain function.
A nationwide cross-sectional study found that Parkinson's patients are more susceptible to severe COVID-19, with increased hospital mortality rates, especially in advanced age groups. The study highlights the need for optimal treatment of Parkinson's patients during the pandemic.
A team of researchers used computational biology and leading-edge experiments to study alpha-synuclein, a protein linked to Parkinson's disease. They found stable conformations that can form complexes with other biomolecules, offering possibilities for developing drugs to regulate the protein's function.
Researchers identify 'antisense long non-coding RNA' regulating tau protein production, a crucial mechanism for brain cell function. The discovery may lead to new treatments for dementia-related diseases, including Parkinson's and Alzheimer's.
A study by Brigham and Women's Hospital has uncovered five genetic locations associated with progression in Parkinson's disease, identifying potential new targets for treatment. The research also developed a risk score to predict progression to dementia, a key factor in quality of life.
A new study wirelessly records human brain activity during daily activities, allowing for adaptive deep brain stimulation and personalized treatment plans. This technology has significant implications for disease management and patient care.
Researchers at UCSF Weill Institute for Neurosciences developed novel neurostimulation devices that monitor brain activity for months, pairing brain recordings with wearable monitors of movement. They identified patterns of brain activity corresponding to specific movement abnormalities associated with Parkinson's disease and demonstra...
Researchers at HKUST create a novel optical tweezers-coupled Raman spectroscopy platform to analyze proteins in low concentrations, particularly IDPs. The study successfully characterizes the structural features of alpha-synuclein, an IDP linked to Parkinson's disease, at physiological concentration.
Researchers develop a robotic-medical device and procedure to safely induce presence hallucinations in Parkinson's patients, providing a new diagnostic tool for the disease. The study findings suggest that the test may help predict the severity of the disease's progression.
Researchers discovered that a protein called VGLUT plays a key role in regulating sex differences in brain vulnerability to age-related dopamine neuron loss. Higher levels of VGLUT were found in female neurons, correlating with greater resilience to neurodegeneration and mobility deficiencies.
A survey by Parkinson's UK found that patients prioritize symptom improvement for balance, walking, and cognitive function. The study highlights the importance of person-centered management and care for improving quality of life.